EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 871 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Using Aspirin to Prevent Breast Cancer Recurrence and Targeted Therapy for... February 14, 2022 The future of research: meet three of our scientists working on... December 13, 2022 Time to get stratified January 10, 2023 Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Load more HOT NEWS How I Rebuilt My Self-Image After a Laryngectomy: A Cancer Survivor’s... Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... Two Early Studies Show Rapid Antitumour CAR-Mediated Responses, but Often of... 2025 ESMO Society Award recipients announced
